Multidimensional assessment of access to medications for opioid use disorder across urban and rural communities: A scoping review

Bommersbach, Tanner J.; Justen, Marissa; Bunting, Amanda M.; Funaro, Melissa; Winstanley, Erin L.; Joudrey, Paul J.

doi:10.1016/j.drugpo.2022.103931

Cited by 12 publications

(2 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, we were unable to capture the experiences of people with a history of injection drug use who do not have access to a telephone. Given the unique urban context of Baltimore with relatively many healthcare resources, it is likely that barriers and facilitators of substance use disorder treatment-related services may differ in rural settings in the US [ 129 ]. We also did not find meaningful differences by age, sex, or race and ethnicity in our sample; however, our sample was skewed toward an older age range.…”

Section: Discussionmentioning

confidence: 99%

Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland

Patel,

Grieb,

Winiker

et al. 2024

Harm Reduct J

View full text Add to dashboard Cite

Background Substance use disorder treatment and recovery support services are critical for achieving and maintaining recovery. There are limited data on how structural and social changes due to the COVID-19 pandemic impacted individual-level experiences with substance use disorder treatment-related services among community-based samples of people who inject drugs. Methods People with a recent history of injection drug use who were enrolled in the community-based AIDS Linked to the IntraVenous Experience study in Baltimore, Maryland participated in a one-time, semi-structured interview between July 2021 and February 2022 about their experiences living through the COVID-19 pandemic (n = 28). An iterative inductive coding process was used to identify themes describing how structural and social changes due to the COVID-19 pandemic affected participants’ experiences with substance use disorder treatment-related services. Results The median age of participants was 54 years (range = 24–73); 10 (36%) participants were female, 16 (57%) were non-Hispanic Black, and 8 (29%) were living with HIV. We identified several structural and social changes due the pandemic that acted as barriers and facilitators to individual-level engagement in treatment with medications for opioid use disorder (MOUD) and recovery support services (e.g., support group meetings). New take-home methadone flexibility policies temporarily facilitated engagement in MOUD treatment, but other pre-existing rigid policies and practices (e.g., zero-tolerance) were counteracting barriers. Changes in the illicit drug market were both a facilitator and barrier to MOUD treatment. Decreased availability and pandemic-related adaptations to in-person services were a barrier to recovery support services. While telehealth expansion facilitated engagement in recovery support group meetings for some participants, other participants faced digital and technological barriers. These changes in service provision also led to diminished perceived quality of both virtual and in-person recovery support group meetings. However, a facilitator of recovery support was increased accessibility of individual service providers (e.g., counselors and Sponsors). Conclusions Structural and social changes across several socioecological levels created new barriers and facilitators of individual-level engagement in substance use disorder treatment-related services. Multilevel interventions are needed to improve access to and engagement in high-quality substance use disorder treatment and recovery support services among people who inject drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland

Patel,

Grieb,

Winiker

et al. 2024

Harm Reduct J

View full text Add to dashboard Cite

show abstract

“…A smaller but still sizable portion of participants (7.5%) switched from one type of MOUD to another type while incarcerated. Changes in type of MOUD received may reflect patient preferences, an understudied factor, 28 which could enhance treatment retention and engagement. [29][30][31] In community settings, patient preference is also related to geographic access to MOUD; the rurality of these jails may impact medication access in the community and preference while incarcerated.…”

Section: Discussionmentioning

confidence: 99%

Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail

2023

View full text Add to dashboard Cite

Objectives: Little is known about the correlates of use of medications to treat opioid use disorder (MOUD, ie, buprenorphine, methadone, naltrexone) offered in jails. We evaluated the implementation and outcomes of a MOUD program offered by 2 of the first jails nationwide to provide access to such care. Methods: We examined use of MOUD among adults with opioid use disorder (n = 347) incarcerated by 2 rural jails in Massachusetts (2018Massachusetts ( -2021. We examined MOUD transitions from intake to during incarceration. Using logistic regression, we examined factors associated with in-jail use of MOUD. Results: At jail entry, 48.7% of individuals with opioid use disorder were being treated with MOUD. During incarceration, 65.1% received MOUD, attributable to a 9.2% increase in use of methadone (from 15.9% to 25.1%) and a 10.1% increase in use of buprenorphine (from 28.5% to 38.6%). During incarceration, 32.3% of individuals were continued on the same MOUD from the community, 25.4% were started, 8.9% stopped, and 7.5% switched type. A total of 25.9% entered jail not on any MOUD and were not started on it. Use of MOUD during incarceration was positively associated with having received MOUD in the community (odds ratio, 12.2; 95% confidence interval, 5.8-25.5) and incarceration at site 1 compared with site 2 (OR, 24.6; 95% CI, 10.9-54.4). Conclusions: Expanded access to MOUD in jails can engage an at-risk population with treatment. Understanding factors related to this population's use of MOUD may aid efforts to optimize care during incarceration and after community re-entry.

show abstract

Opioid Use Disorder and Overdose in the First Year Postpartum: A Rapid Scoping Review and Implications for Future Research

Frankeberger

Jarlenski

Coulter

et al. 2023

Matern Child Health J

View full text Add to dashboard Cite

Multidimensional assessment of access to medications for opioid use disorder across urban and rural communities: A scoping review

Cited by 12 publications

References 59 publications

Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland

Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland

Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail

Opioid Use Disorder and Overdose in the First Year Postpartum: A Rapid Scoping Review and Implications for Future Research

Contact Info

Product

Resources

About